RecruitingPHASE2, PHASE3NCT06111638

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Studying Hemophilia

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Shanghai Xinzhi BioMed Co., Ltd.
Principal Investigator: Lei Zhang, MD
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
Intervention: Single dose intravenous injection of BBM-H803(genetic)
Enrollment: 55 enrolled
Eligibility: 18 years · MALE
Timeline: 2024 – 2031

Study locations (10)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
Southern Hospital, Southern Medical University, Guangzhou, Guangdong, China
Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Wuhan Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, Hubei, China
Xiangya Hospital Central South University, Changsha, Hunan, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The Affiliated Hospital of Northwest University Xi'an No.3 Hospital, Xi’an, Shanxi, China
Sichuan Provincial People's Hospital, Chengde, Sichuan, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

Collaborators

Shanghai Mianyi Biopharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06111638 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials